<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0CEC6E19-2999-49FF-95D0-6A682CEB301E"><gtr:id>0CEC6E19-2999-49FF-95D0-6A682CEB301E</gtr:id><gtr:firstName>Wolf</gtr:firstName><gtr:surname>Reik</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E80CF82D-EF99-4480-9D13-F12A0B7E8363"><gtr:id>E80CF82D-EF99-4480-9D13-F12A0B7E8363</gtr:id><gtr:firstName>Llewelyn</gtr:firstName><gtr:surname>Roderick</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F0000C237"><gtr:id>87A87E29-88D9-4255-ABFC-835E30A0E5FE</gtr:id><gtr:title>A study of the epigenetic alterations that result in cardiac hypertrophy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/0000C237</gtr:grantReference><gtr:abstractText>Heart disease is a significant cause of mortality in the developed world. In 2004 it was responsible for 137,700 deaths in the UK, equating to 24% of all deaths. A major predictor of mortality due to heart disease is cardiac hypertrophy (an increase in cell size without increase in cell number), and it is the most important risk factor for heart failure in humans. Hypertrophy can however also be a beneficial adaptive response providing the increased blood supply required during pregnancy and to sustain levels of increased physical activity experienced by athletes. Cardiac hypertrophy is characterised by an increase in the muscle mass/size of the heart due to enlargement of heart cells without any proliferation. This increase in heart size is caused by a significant change in the expression levels of a number of genes (the copying of DNA information into RNA and then oftern into protein). This remodelling of gene expression is controlled by factors (transcription factors) that bind to the DNA as well as by proteins that modify the structure and packaging of DNA. In this study, we plan to investigate the mechanisms that control suppression of gene transcription and whether these differ between the poorly reversible pathological forms of hypertrophy and the more reversible compensated hypertrophy.</gtr:abstractText><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>60517</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Institute for Experimental Medical Research</gtr:department><gtr:description>Norway Rats</gtr:description><gtr:id>81657482-8B31-4268-839B-ED7515B84BA7</gtr:id><gtr:impact>Publication in JCB in 2012
27893464
23166348</gtr:impact><gtr:outcomeId>EH4BuwbJM5e-1</gtr:outcomeId><gtr:partnerContribution>Provision and phenotyping of hearts hypertrophic due to exercise, aortic banding or ageing.</gtr:partnerContribution><gtr:piContribution>Analysis of Cardiac Myocyte proteome, transcriptome and epigenome.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Foo Addenbrookes</gtr:description><gtr:id>B0C7B36E-E42F-4B3A-999C-BA0D9F682BFE</gtr:id><gtr:impact>Publications in PNAS and Channels in 2009
25784084</gtr:impact><gtr:outcomeId>nb38Ds3VKMt-1</gtr:outcomeId><gtr:partnerContribution>Provision of human hypertrophic heart tissue and histology of heart tissue</gtr:partnerContribution><gtr:piContribution>Analysis of hypertrophic cardiac myocytes from human.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Cell and Molecular Biology</gtr:department><gtr:description>Nuclear Isolation</gtr:description><gtr:id>41B5CF84-FD9D-47F5-AAFC-4D71F7E49741</gtr:id><gtr:impact>27893464</gtr:impact><gtr:outcomeId>B1G2G5E21ZF-1</gtr:outcomeId><gtr:partnerContribution>Provision of nuclei from human cardiac myocytes</gtr:partnerContribution><gtr:piContribution>Analysis of transcriptome and epigenome of human cardiomyocyte nuclei</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Royal Society Summer Exhibition 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5837CEE6-6BE3-4069-8024-5B287A4979EB</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>f6XbL6aSErx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Late nite lab 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2E4CE3DD-C998-4174-858B-462D9655A3B5</gtr:id><gtr:impact>Adults attended an open evening with talks and exhibits from scientific departments from the Cambridge area. Our research was explained and science in general discussed during a drinks reception.

Several parents asked for guidance regarding scientific careers for their children</gtr:impact><gtr:outcomeId>NsmL4EMBZVG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>837974</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Odysseus FWO</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Research Foundation - Flanders (FWO)</gtr:fundingOrg><gtr:fundingRef>90663</gtr:fundingRef><gtr:id>41CA5231-0BB0-41EA-A0D2-EAA2EAF3BAC8</gtr:id><gtr:outcomeId>56e01771321a58.41791742</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>in response to different stresses, the heart grows. This may be as a result of diseases such as myocardial infarction, as a result of chronic exercise or pregnancy. Although heart growth in response to the physiological stimuli is beneficial, when induced by disease, the heart growth is no beneficial and is often a prequel to heart failure - when the heart cannot provide for the body. 
In this project we analysed how the genes changed following the different growth stimuli were regulated. We found that changes in the epigenome - the way DNA is packed and regulated in a cell - were altered. The epigenome was altered in a different way for the different growth stimuli. 
We also identified how these changes in the epigenome were brought about. 
As well as identifying what changes in the epigenome happened in physiological vs pathological cardiac growth, we identified how this was brought about and the enzymes and molecules involved. 
This work is now published in the Journal of Clinical Investigation .</gtr:description><gtr:exploitationPathways>The work remains to be published but will no doubt identify new ways by which heart growth and cell division can be manipulated to enhance function. 
For e.g. increase cardiac regeneration during damage or reverse the maladaptive growth. 

Our findings suggest strategies to enhance cardiac regeneration and to prevent maladaptive cardiac growth. 
The molecules that we identified that are involved in these processes are being further probed to test their utility for therapy.</gtr:exploitationPathways><gtr:id>E33F876C-5713-48A4-A169-5A2AC8F1E532</gtr:id><gtr:outcomeId>56e17994066522.95035990</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>https://www.jci.org/articles/view/88353</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>36D58FAF-F982-4960-925D-24C5017B79D0</gtr:id><gtr:title>The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60352fe93a104bfe9f4e5d05a87507cc"><gtr:id>60352fe93a104bfe9f4e5d05a87507cc</gtr:id><gtr:otherNames>Thienpont B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>591b192c03ad81.21228920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C87111EC-5E7F-4C66-A3BA-73FCE6D3E9F9</gtr:id><gtr:title>Epigenetics in the heart: the role of histone modifications in cardiac remodelling.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/978cc3b8628e6a13b2f043816a52c860"><gtr:id>978cc3b8628e6a13b2f043816a52c860</gtr:id><gtr:otherNames>Tingare A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_16328_28_23697939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38AA6F4F-60DB-44C0-96FC-6D5DB666EB6D</gtr:id><gtr:title>Experimental heart failure modelled by the cardiomyocyte-specific loss of an epigenome modifier, DNMT3B.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c537b3344e62e3421dabebb66adf1c9c"><gtr:id>c537b3344e62e3421dabebb66adf1c9c</gtr:id><gtr:otherNames>Vujic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn><gtr:outcomeId>56e00a45155b15.62699227</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/0000C237</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>